Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2012

01-03-2012 | Original Article

Hearing loss in patients with mucopolysaccharidosis II: Data from HOS – the Hunter Outcome Survey

Authors: Annerose Keilmann, Todsaporn Nakarat, Iain A. Bruce, David Molter, Gunilla Malm, on behalf of the HOS Investigators

Published in: Journal of Inherited Metabolic Disease | Issue 2/2012

Login to get access

Abstract

Background

Subjectively reported hearing loss is a common feature of mucopolysaccharidosis II (MPS II, Hunter syndrome). This study provides an epidemiological description of hearing loss and other otolaryngological manifestations reported by patients registered in the Hunter Outcome Survey (HOS), an international registry of patients with MPS II.

Methods

Data about ear signs and symptoms were available for 554 of the 605 patients alive at HOS entry. The degree of hearing loss for 162 pure-tone audiograms (PTAs) from 83 patients was classified by independent interpreters using both the age-specific International Institute of Standardization (ISO) 7029 standard and the age-independent World Health Organization (WHO) clinical guidelines. A linear regression analysis using cross-sectional data was conducted to investigate the relationship between hearing loss and age.

Results

The most prevalent otolaryngological manifestations and interventions reported were otitis (either acute otitis media or chronic otitis media [72%]), hearing loss (67%), insertion of ventilation tubes (50%), adenoidectomy (47%), and hearing aids (41%). According to the ISO standard, only one patient out of the 83 with audiogram data in HOS had normal hearing in both ears at all time points. According to the WHO classification, 16% had normal hearing; hearing loss was mild in 24%, moderate in 31%, severe in 22%, and profound in 7%. In the linear regression analysis, the hearing threshold in the cohort increased with age at an estimated rate of approximately 1 dB per year.

Conclusions

Hearing impairment is common in MPS II. Early otolaryngological evaluation and intervention is recommended.
Literature
go back to reference Al Sawaf S, Mayatepek E, Hoffmann B (2008) Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 31:473–480PubMedCrossRef Al Sawaf S, Mayatepek E, Hoffmann B (2008) Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 31:473–480PubMedCrossRef
go back to reference Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRef Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRef
go back to reference Downs AT, Crisp T, Ferretti G (1995) Hunter’s syndrome and oral manifestations: a review. Pediatr Dent 17:98–100PubMed Downs AT, Crisp T, Ferretti G (1995) Hunter’s syndrome and oral manifestations: a review. Pediatr Dent 17:98–100PubMed
go back to reference Friedmann I, Spellacy E, Crow J, Watts RW (1985) Histopathological studies of the temporal bones in Hurler's disease [mucopolysaccharidosis (MPS) IH]. J Laryngol Otol 99:29–41PubMedCrossRef Friedmann I, Spellacy E, Crow J, Watts RW (1985) Histopathological studies of the temporal bones in Hurler's disease [mucopolysaccharidosis (MPS) IH]. J Laryngol Otol 99:29–41PubMedCrossRef
go back to reference Hayes E, Babin R, Platz C (1980) The otologic manifestations of mucopolysaccharidoses. Am J Otol 2:65–69PubMed Hayes E, Babin R, Platz C (1980) The otologic manifestations of mucopolysaccharidoses. Am J Otol 2:65–69PubMed
go back to reference Hopkins R, Watson JA, Jones JH, Walker M (1973) Two cases of Hunter’s syndrome – the anaesthetic and operative difficulties in oral surgery. Br J Oral Surg 10:286–299PubMedCrossRef Hopkins R, Watson JA, Jones JH, Walker M (1973) Two cases of Hunter’s syndrome – the anaesthetic and operative difficulties in oral surgery. Br J Oral Surg 10:286–299PubMedCrossRef
go back to reference International Organization for Standardization (2000). Acoustics - Statistical distribution of hearing thresholds as a function of age, ISO 7029:2000. Retrieved from http://www.iso.org on 11-12-10. International Organization for Standardization (2000). Acoustics - Statistical distribution of hearing thresholds as a function of age, ISO 7029:2000. Retrieved from http://​www.​iso.​org on 11-12-10.
go back to reference Jassar P, Coatesworth A, Strachan DR (2004) Long-term ventilation of the middle ear using a subannular tympanotomy technique: a follow-up study. J Laryngol Otol 118:933–936PubMedCrossRef Jassar P, Coatesworth A, Strachan DR (2004) Long-term ventilation of the middle ear using a subannular tympanotomy technique: a follow-up study. J Laryngol Otol 118:933–936PubMedCrossRef
go back to reference Keilmann A, Hajioff D, Ramaswami U, Investigators FOS (2009) Ear symptoms in children with Fabry disease: data from the Fabry outcome survey. J Inherit Metab Dis 32:739–744PubMedCrossRef Keilmann A, Hajioff D, Ramaswami U, Investigators FOS (2009) Ear symptoms in children with Fabry disease: data from the Fabry outcome survey. J Inherit Metab Dis 32:739–744PubMedCrossRef
go back to reference Komura Y, Kaga K, Ogawa Y, Yamaguchi Y, Tsuzuku T, Suzuki JI (1998) ABR and temporal bone pathology in Hurler’s disease. Int J Pediatr Otorhinolaryngol 43:179–188PubMedCrossRef Komura Y, Kaga K, Ogawa Y, Yamaguchi Y, Tsuzuku T, Suzuki JI (1998) ABR and temporal bone pathology in Hurler’s disease. Int J Pediatr Otorhinolaryngol 43:179–188PubMedCrossRef
go back to reference Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121:e377–e386PubMedCrossRef Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121:e377–e386PubMedCrossRef
go back to reference Mazzoli M, Van Camp G, Newton V, Giarbini N, Declau F, Parving A (2003) Recommendations for the description of genetic and audiological data for families with nonsyndromic hereditary hearing impairment. Audiolog Med 1:148–150CrossRef Mazzoli M, Van Camp G, Newton V, Giarbini N, Declau F, Parving A (2003) Recommendations for the description of genetic and audiological data for families with nonsyndromic hereditary hearing impairment. Audiolog Med 1:148–150CrossRef
go back to reference Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254PubMedCrossRef Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254PubMedCrossRef
go back to reference Mendelsohn N, Harmatz P, Bodamer O et al (2010) Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey (HOS). Genet Med 12:816–822PubMedCrossRef Mendelsohn N, Harmatz P, Bodamer O et al (2010) Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey (HOS). Genet Med 12:816–822PubMedCrossRef
go back to reference Motamed M, Thorne S, Narula A (2000) Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 53:121–124PubMedCrossRef Motamed M, Thorne S, Narula A (2000) Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 53:121–124PubMedCrossRef
go back to reference Muenzer J (2004) The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 144:S27–S34PubMedCrossRef Muenzer J (2004) The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 144:S27–S34PubMedCrossRef
go back to reference Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473PubMedCrossRef Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473PubMedCrossRef
go back to reference Napiontek U, Keilmann A (2006) Hearing impairment in patients with mucopolysaccharidoses. Acta Paediatrica Suppl 451:113–117 Napiontek U, Keilmann A (2006) Hearing impairment in patients with mucopolysaccharidoses. Acta Paediatrica Suppl 451:113–117
go back to reference Pascolini D, Smith A (2009) Hearing impairment in 2008: a compilation of available epidemiological studies. Int J Audiol 48:473–485PubMedCrossRef Pascolini D, Smith A (2009) Hearing impairment in 2008: a compilation of available epidemiological studies. Int J Audiol 48:473–485PubMedCrossRef
go back to reference Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP (2005) Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 69:589–595PubMedCrossRef Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP (2005) Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 69:589–595PubMedCrossRef
go back to reference Walker RW, Darowski M, Morris P, Wraith JE (1994) Anaesthesia and mucopolysaccharidoses. A review of airway problems in children Anaesthesia 49:1078–1084 Walker RW, Darowski M, Morris P, Wraith JE (1994) Anaesthesia and mucopolysaccharidoses. A review of airway problems in children Anaesthesia 49:1078–1084
go back to reference Wold SM, Derkay CS, Darrow DH, Proud V (2010) Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 74:27–31PubMedCrossRef Wold SM, Derkay CS, Darrow DH, Proud V (2010) Role of the pediatric otolaryngologist in diagnosis and management of children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 74:27–31PubMedCrossRef
go back to reference Wraith JE, Beck M, Giugliani R et al (2008) Initial report from the Hunter Outcome Survey. Genet Med 10:508–516PubMedCrossRef Wraith JE, Beck M, Giugliani R et al (2008) Initial report from the Hunter Outcome Survey. Genet Med 10:508–516PubMedCrossRef
go back to reference Yoshinaga-Itano C (2003) From screening to early identification and intervention: discovering predictors to successful outcomes for children with significant hearing loss. J Deaf Stud Deaf Educ 8:11–30PubMedCrossRef Yoshinaga-Itano C (2003) From screening to early identification and intervention: discovering predictors to successful outcomes for children with significant hearing loss. J Deaf Stud Deaf Educ 8:11–30PubMedCrossRef
go back to reference Young ID, Harper PS (1981) Psychosocial problems in Hunter’s syndrome. Child Care Health Dev 7:201–209PubMedCrossRef Young ID, Harper PS (1981) Psychosocial problems in Hunter’s syndrome. Child Care Health Dev 7:201–209PubMedCrossRef
go back to reference Young ID, Harper PS (1983) The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev Med Child Neurol 25:481–489PubMedCrossRef Young ID, Harper PS (1983) The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev Med Child Neurol 25:481–489PubMedCrossRef
Metadata
Title
Hearing loss in patients with mucopolysaccharidosis II: Data from HOS – the Hunter Outcome Survey
Authors
Annerose Keilmann
Todsaporn Nakarat
Iain A. Bruce
David Molter
Gunilla Malm
on behalf of the HOS Investigators
Publication date
01-03-2012
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2012
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-011-9378-5

Other articles of this Issue 2/2012

Journal of Inherited Metabolic Disease 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.